苏州大学附属第二医院
Second Affiliated Hospital of Soochow University
在本站收录的 53 种疾病中,这家医院列在其中 12 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
苏州大学附属第二医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma5 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
- 胃癌Stomach cancer32 篇牵头论文
- 骨肉瘤Osteosarcoma13 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
- 尤文肉瘤Ewing sarcoma2 篇牵头论文
- 多发性骨髓瘤Multiple myeloma2 篇牵头论文
- 法布雷病Fabry disease0 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
- 白塞病Behçet disease1 篇牵头论文
- IgA 肾病IgA nephropathy1 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
未列出的收录疾病:肝细胞癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、神经母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 2 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。
这些数字背后的记录
牵头的论文5
- Antitumor/anti-inflammatory effects/tissue healing as an all-in-one therapeutic strategy for nasopharyngeal carcinoma.
- First report of opportunistic screening for nasopharyngeal carcinoma by gastroscopy.
- Preliminary study on the correlation between thyroid magnetic resonance parameters and radiation dose after radiotherapy for nasopharyngeal carcinoma.
- Difference after radiotherapy observed in patients with nasopharyngeal carcinoma.
- T1-2N1M0 nasopharyngeal carcinoma chemotherapy or not: A retrospective study.
PubMed 以外找到的论文(未计入)3
- Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma
- Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase
- Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 4 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文4
- Characterization of tertiary lymphoid structure identifies competitive binding of CD40 and STING with TRAF2 driving IRF4-mediated B cell activation in esophageal squamous cell carcinoma.
- Involvement of circRNA Regulators MBNL1 and QKI in the Progression of Esophageal Squamous Cell Carcinoma.
- Impact of the extent of recurrent laryngeal nerve lymphadenectomy on thoracic esophageal squamous cell carcinoma: a real-world multicentre study.
- Silencing FAM135B enhances radiosensitivity of esophageal carcinoma cell.
PubMed 以外找到的论文(未计入)2
- 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 32 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
苏州有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- 分期
- 不分期
- 开始
- 2026-06
- 登记号
- NCT07552402
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南宁、大连、成都、杭州、武汉、石家庄、福州、苏州、银川
- 正在招募Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- 分期
- III期
- 开始
- 2025-02
- 登记号
- NCT06731478
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文32
- Machine learning models for prediction of lymph node metastasis in patients with gastric cancer: a Chinese single-centre study with external validation in an Asian American population.
- Development and current status of anti-reflux esophagogastrostomy after proximal gastrectomy: a literature review.
- Development and Characterization of the [177Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model.
- Postoperative hypotension in gastric cancer patients: causes and clinical approaches.
- Metabolic regulation of amino acids provides an important basis for individualized nutritional therapy for patients with gastric cancer during the perioperative period.
- Incidence and risk of remnant gastric cancer after gastrectomy for gastric cancer: a population-based study from the SEER database.
- A case-series study of hepatic left lateral segment inversion for surgical field exposure in laparoscopic gastrectomy.
- Tumor-derived Prevotella intermedia aggravates gastric cancer by enhancing Perilipin 3 expression.
- DDX24 promotes tumor progression by mediating hexokinase-1 induced glycolysis in gastric cancer.
- MiR-30a-5p isoform -1|1 promotes the progression of gastric cancer by inhibiting TMEM66 and reducing intratumoral cytotoxic T cells.
- Investigating MATN3 and ASPN as novel drivers of gastric cancer progression via EMT pathways.
- CircFNTA promotes tumorigenesis and progression of gastric cancer via miR-604/miR-647/SCN8A axis.
- The relationship between splenic dose and radiation-induced lymphopenia.
- RAI2 acts as a tumor suppressor with functional significance in gastric cancer.
- High expression of serine protease 2 (PRSS2) associated with invasion, metastasis, and proliferation in gastric cancer.
- Decreased KLF3 Expression via miR-660-5p Targeting Suppresses Gastric Cancer Cell Progression.
- METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma.
- Peripheral CD4+CD25hiCD127low regulatory T cells are increased in patients with gastrointestinal cancer.
- Laparoscopic proximal gastrectomy with right-sided overlap and single-flap valvuloplasty (ROSF): a case-series study.
- Development and validation of a multiphase CT radiomics nomogram for the preoperative prediction of lymphovascular invasion in patients with gastric cancer.
- Exosomal circ_0091741 promotes gastric cancer cell autophagy and chemoresistance via the miR-330-3p/TRIM14/Dvl2/Wnt/β-catenin axis.
- MST4 as a novel therapeutic target for autophagy and radiosensitivity in gastric cancer.
- Targeting ROR1 inhibits glucocorticoid-induced gastric cancer growth.
- Inhibition of Musashi-1 enhances chemotherapeutic sensitivity in gastric cancer patient-derived xenografts.
- PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report.
- Current status of internal hernia after gastrectomy for gastric cancer.
- Clinicopathological Analysis and Prognostic Assessment of TCN1 in Patients with Gastric Cancer.
- Current status of laparoscopic proximal gastrectomy in proximal gastric cancer: Technical details and oncologic outcomes.
- TYMSOS drives the proliferation, migration, and invasion of gastric cancer cells by regulating ZNF703 via sponging miR-4739.
- Mast1 mediates radiation-induced gastric injury via the P38 MAPK pathway.
- Esophagus two-step-cut overlap method in esophagojejunostomy after laparoscopic gastrectomy.
- UFBP1, a key component in ufmylation, enhances drug sensitivity by promoting proteasomal degradation of oxidative stress-response transcription factor Nrf2.
中文论文(未计入)4
- [Application status of vagus nerve preservation and double-flap technique in laparoscopic proximal gastrectomy].
- [Artificial intelligence for lymph node metastasis prediction in gastric cancer: research progress].
- [A preliminary exploration of reduced port laparoscopic proximal gastrectomy with right-sided overlap and single-flap valvuloplasty (ROSF)].
- [Immune-Related Pancreatitis Caused by Immune Checkpoint Inhibitor Nivolumab:Report of One Case].
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
- Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 14 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文13
- STUB1-mediated ubiquitination of SLC25A10 regulates mitochondrial function and drives osteosarcoma progression: A novel therapeutic target.
- KAT7 serves as an oncogenic gene and regulates CCL3 expression via STAT1 signaling in osteosarcoma.
- Relationship between surgical compliance and survival outcome in patients with Ewing sarcoma.
- Mitochondria targeted biomimetic platform for chemo/photodynamic combination therapy against osteosarcoma.
- A Feedback Loop of LINC00665 and the Wnt Signaling Pathway Expedites Osteosarcoma Cell Proliferation, Invasion, and Epithelial-Mesenchymal Transition.
- ADCK1 is a potential therapeutic target of osteosarcoma.
- Identification of Gαi3 as a promising target for osteosarcoma treatment.
- Gliosarcoma with osteosarcomatous component: A case report and short review illustration.
- LncRNA LOC100129620 promotes osteosarcoma progression through regulating CDK6 expression, tumor angiogenesis, and macrophage polarization.
- COL3A1 and Its Related Molecules as Potential Biomarkers in the Development of Human Ewing's Sarcoma.
- ARHGEF3 Associated with Invasion, Metastasis, and Proliferation in Human Osteosarcoma.
- miRNA-296-5p functions as a potential tumor suppressor in human osteosarcoma by targeting SND1.
- Propofol suppresses osteosarcoma cell function by regulating FOXO1/TUSC7.
早期论文(2016–2020 年)9
- MicroRNA-187 suppresses the proliferation migration and invasion of human osteosarcoma cells by targeting MAPK7.
- High Expression of N-Acetylgalactosaminyl-transferase 1 (GALNT1) Associated with Invasion, Metastasis, and Proliferation in Osteosarcoma.
- Proliferation inhibition and apoptosis promotion by dual silencing of VEGF and Survivin in human osteosarcoma.
- EP1 receptor is involved in prostaglandin E2-induced osteosarcoma growth.
- TCF3-activated LINC00152 exerts oncogenic role in osteosarcoma through regulating miR-1182/CDK14 axis.
- Long noncoding RNA SNHG6 promotes osteosarcoma cell proliferation through regulating p21 and KLF2.
- MiR-299-5p targets cell cycle to promote cell proliferation and progression of osteosarcoma.
- The anti-tumor effect of pachymic acid on osteosarcoma cells by inducing PTEN and Caspase 3/7-dependent apoptosis.
- miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 7 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
苏州有 2 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
- 正在招募A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- 分期
- I期
- 开始
- 2025-12
- 登记号
- NCT07179679
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、南京、南充、南昌、广州、承德、苏州、西安、重庆
- 正在招募UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
- 分期
- 不分期
- 开始
- 2024-04
- 登记号
- NCT06279026
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
中文论文(未计入)5
- [The Role and Possible Mechanism of T Cell Costimulatory Molecule CD28 Activation in Pathogenesis of Multiple Myeloma].
- [The Impact of SRSF1 -Mediated Alternative Splicing of RBBP6 on the Proliferation of Multiple Myeloma Cells].
- [Bone Marrow Adipocytes Promote the Survival of Multiple Myeloma Cells and Up-Regulate Their Chemoresistance].
- [Clinical Significance of CD28 Expression in Newly Diagnosed Multiple Myeloma].
- [Effect of the Connexin 43 Coupling to the Biobehavior of Multiple Myeloma Cells].
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
- Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
- A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
- Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma
其他疾病
法布雷病
Fabry disease2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在法布雷病下全国有 80 家医院列在法布雷病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在白塞病下全国有 139 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 6 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- A Pharmacokinetic Study of Budesonide Delayed Release Tablet D23A (D23) in Healthy Chinese Participants Under Fasting Conditions
- A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 4 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
联系这家医院
出示给工作人员或司机的院名卡
苏州大学附属第二医院
Second Affiliated Hospital of Soochow University
苏州
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药